Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 5/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14706993 | 0.75 | MAPK1 (0.40) | MAPK1SMN1; SMN2HCAR2KDM1ASLC18A3 | |
| SCHEMBL14707058 | 0.74 | HTR2A (0.49) | MAPK1SMN1; SMN2KDM1ASLC18A3SIGMAR1 | |
| SCHEMBL11772061 | 0.70 | HTR2A (0.42) | MAPK1SMN1; SMN2HCAR2KDM1ASIGMAR1 | |
| SCHEMBL15908331 | 0.70 | KDM1A (0.42) | HCAR2KDM1ASIGMAR1MAOBHTR2A | |
| SCHEMBL15908327 | 0.69 | KDM1A (0.45) | HCAR2KDM1ASIGMAR1HTR2A | |
| SCHEMBL31683810 | 0.68 | AVPR1A (0.49) | HCAR2KDM1AMAOBHTR2A | |
| SCHEMBL11701139 | 0.68 | SIGMAR1 (0.57) | MAPK1SLC18A3SIGMAR1HTR2A | |
| SCHEMBL3400210 | 0.67 | SIGMAR1 (0.46) | SIGMAR1 | |
| Methane SCHEMBL11703509 | 0.67 | SIGMAR1 (0.56) | MAPK1SLC18A3SIGMAR1HTR2A | |
| SCHEMBL3400212 | 0.67 | SIGMAR1 (0.46) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540358-B2 | Tricyclic compounds as anticancer agents | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | MT. SINAI SCHOOL OF MEDICINE (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213578-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TFEB, FOXO3, FOXO1 | MAPK1 1375/4885SMN1; SMN2 4863/4885HCAR2 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.